$MTVA Holding For The Presentation 🚀 🔹 MetaVia still feels like it has more room to run as GLP-1 obesity names stay hot 📈 🔹 Company is advancing DA-1726, a

$MTVA Holding For The Presentation 🚀 🔹 MetaVia still feels like it has more room to run as GLP-1 obesity names stay hot 📈 🔹 Company is advancing DA-1726, a GLP-1/glucagon dual agonist targeting obesity + metabolic disease 🔥 🔹 Upcoming presentation could put more eyes on the weight-loss pipelin…